# CAR-T Kidney Care: Anticipate Systemic Toxicity

Track kidney recovery and persistent electrolyte abnormalities. Do not carry forward unverified product indications or mechanistic claims from a rapidly evolving field.

![Infographic: CAR-T Kidney Care: Anticipate Systemic Toxicity](https://urinenephrology.org/visual-reference/images/mastery-car-t.png?v=20261003c)

## Immune activation affects organs

Cellular therapy can trigger inflammatory syndromes with hemodynamic instability and kidney stress. AKI may also reflect infection, drugs, tumor lysis, or prior disease.

## Recognize CRS with ASTCT criteria

CRS begins with fever ≥38°C not explained by another cause; severity is determined by the more severe hypotension or oxygen-support requirement. Once anti-cytokine or antipyretic treatment has begun for CRS, fever is not required for subsequent grading. Infection can coexist and still requires evaluation.

## Keep alternatives active

Cytokine-release syndrome and infection can overlap. Evaluate perfusion, cultures, medications, electrolyte changes, and tumor burden rather than assigning every AKI to one cause.

## Coordinate with the cellular-therapy team

Use the current product-specific and institutionally approved grading and treatment pathway. Renal dose adjustment and supportive care require shared decisions.

## Explain the electrolyte abnormality

For falling potassium or phosphate, assess intake, gastrointestinal loss, drugs, renal wasting, and intracellular shifts. B-cell depletion is not a valid explanation based on loss of the body’s potassium stores. Replace according to severity and kidney function while monitoring magnesium, rhythm, and ongoing losses.

## Follow beyond the acute phase

Track kidney recovery and persistent electrolyte abnormalities. Do not carry forward unverified product indications or mechanistic claims from a rapidly evolving field.

## Supporting evidence

- [PubMed 30592986](https://pubmed.ncbi.nlm.nih.gov/30592986/)

## Source lessons

- [car t therapy kidney review](https://urinenephrology.org/mastery/onconephrology/car-t-therapy-kidney-review.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.